Navigation Links
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
Date:8/14/2009

EMERYVILLE, Calif., Aug. 14 /PRNewswire-FirstCall/ -- NovaBay((R)) Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections without causing resistance, reported today its financial results and operational highlights for the second quarter of 2009 ended June 30, 2009.

License and collaboration revenue for the second quarter of 2009 increased $ 0.9 million to $2.3 million from $1.4 million for the second quarter of 2008. This revenue consisted almost exclusively of amounts earned under the license and collaboration agreements with Alcon (NYSE: ACL), and beginning with this quarter, Galderma S.A., for amortization of the upfront technology access fees, receipt of milestone payments, and other amounts that have been reimbursed for the funding of research and development activities performed during the period.

The net loss for the second quarter of 2009 was $0.3 million, or $0.01 per share, compared to a net loss of $2.4 million, or $0.11 per share, reported for the second quarter of 2008. As of June 30, 2009, the company's cash, cash equivalents and short-term investments totaled $10.7 million, a net decrease of only $1.4 million from the $12.1 million reported at December 31, 2008. This represents a 75% reduction from the $5.5 million decrease during the first six months of 2008. The decreased burn rate in 2009 was largely due to cost containment measures, delayed research, development, and clinical expenses and receipt of a milestone and higher reimbursement payments from Alcon and upfront payments fr
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
2. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
3. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
4. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
5. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
6. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
11. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)...  WIRB-Copernicus Group (WCG), the world,s largest provider ... research, announced today that its Western Institutional Review ... the Association for the Accreditation of Human Research ... for clinical research participants. WCG Chairman ... commented, "It is of utmost importance to WCG ...
(Date:9/22/2014)... METTLER TOLEDO is pleased to ... device CNS110 ScanTape™ . Replacing a traditional ... greater ease and accuracy for transport and logistics ... enhance productivity—an important benefit for load planning and ... profits. , Usable at any point in ...
(Date:9/22/2014)... -- Spherix Incorporated (SPEX) -- an intellectual property development company committed ... that the United States Patent & Trademark Office (USPTO) issued ... September that is part of a standard essential family of ... , Application number: US 13/728,867 , Publication date: ... The listed inventors of the new patent, ...
(Date:9/21/2014)... how to produce ultra-thin "diamond nanothreads" that promise extraordinary ... today,s strongest nanotubes and polymers. A paper describing this ... Badding, a professor of chemistry at Penn State University, ... of the journal Nature Materials . , "From ... because the threads we formed have a structure that ...
Breaking Biology Technology:Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2ScanTape™ Handheld Dimensioner Increases Processing Volume 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4
... meal if certain protein components are experimentally disrupted, a ... discovered. The approach could be used as an ... diseases like dengue fever, yellow fever and malaria. ... vesicle transport, on which the mosquitoes rely to release ...
... on the buttock or the delicately soft entry of a blood ... "how" to use those tiny "molecular syringes" which are carbon nanotubes. ... (nanometre) and a maximum length of just a few millimetres, the ... ethereal tubes - the smallest ever made by man - is ...
... LOS ANGELES, July 18, 2011 Genesis Biopharma, Inc. ... today announced it has named David Voyticky to its ... Miller Energy Resources (NYSE: MILL ), an ... 16 years of experience in corporate finance and merger ...
Cached Biology Technology:Making blood-sucking deadly for mosquitoes 2Making blood-sucking deadly for mosquitoes 3Making blood-sucking deadly for mosquitoes 4Nanotech: injections or sampling? New 'molecular syringes' under testing 2Genesis Biopharma Names David Voyticky to Board of Directors 2
(Date:9/21/2014)... as mussels and barnacles secrete very sticky proteins that ... underwater. Inspired by these natural adhesives, a team of ... used to repair ships or help heal wounds and ... the MIT researchers engineered bacteria to produce a hybrid ... as a bacterial protein found in biofilms slimy ...
(Date:9/19/2014)... biology professor will study the unique bioelectric signaling system ... benefit people,s health. The OU researcher is working ... to produce the signals used to map the world ... a rate of 500-600 discharges a second throughout their ... fish are extreme, but necessary for survival. , "There ...
(Date:9/19/2014)... Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: NXTD ... focused on the growing m-commerce market, updates the "Wocket in Your ... the lightweight and light middleweight weight classes, Vinny Pazienza ... announced that Game of Thrones actor Ciaran Hinds ... Children star Katey Sagal have been cast in ...
Breaking Biology News(10 mins):Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3
... 12, 2010 How toxic, blue-green algae out-compete other ... by so doing proliferate dangerously in freshwater bodies -- ... University of Jerusalem. In general, the increasing ... bodies is a matter of growing international concern due ...
... drugs free of charge so that customers can neutralise the ... London suggest in a new study published this week. ... blood. A wealth of trial data has proven them to ... In a paper published in the Sunday 15 August ...
... Cold Spring Harbor, N.Y. Hematopoietic stem cells (HSCs) have ... self-renew and to develop into any kind of blood cell, ... system. Scientists have traced these qualities to a distinct locale ... on, but the identity and function of the niche-forming constituents ...
Cached Biology News:How algae 'enslavement' threatens freshwater bodies described by Hebrew University researcher 2Free statins with fast food could neutralize heart risk, scientists say 2Researchers find that one type of stem cell creates a niche for another type in bone marrow 2Researchers find that one type of stem cell creates a niche for another type in bone marrow 3
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
...
... Western Blot Strong Antibody Stripping Solution is ... blots that have been developed with chemiluminescence ... is not recommended for stripping colorimetric substrates ... not possible to effectively remove substrates that ...
Biology Products: